Company: DMAC
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001437749-25-024956
Chunk: 1

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-06
Form: 8-K
Item: Item 7.01
Chunk 1
---
Item 7.01

Regulation FD Disclosure.

The Company announced the appointment of Julie Krop, M. D. as Chief Medical Officer of the Company in a press release issued on August 6, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information furnished under this Item 7.01 and Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed “filed” for the purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing by the Company under the Exchange Act or the United States Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

Item 8.01 Other Events.